To understand the relationship between Hub-EGFR.Sig and the immunotherapy prognosis of pan-cancer, PFI were calculated, and the results indicated that patients with higher scores of Hub-EGFR.Sig had a worse prognosis in the training set (P = 0.045, Figure 6E). This evidence concerns the gene EGFR and cancer.